Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies.

  title={Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies.},
  author={Julie Gertner-dardenne and Cécile Bonnafous and Christine Bezombes and Aude-H{\'e}l{\`e}ne Capietto and Virginie Scaglione and Sophie Ingoure and Delphine Cendron and Emilie T. E. Gross and J. F. Lepage and Anne Quillet-Mary and Loic Ysebaert and Guy Laurent and Hélène Sicard and Jean-Jacques Fourni{\'e}},
  volume={113 20},
In human blood, 1% to 5% of lymphocytes are gammadelta T cells; they mostly express the gammadelta T-cell receptor (TCR)Vgamma9, recognize nonpeptide phosphoantigens (PAgs) produced by microbes and tumor cells, and mediate different modes of lytic activities directed against tumor target cells. Antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by cytolytic lymphoid cells is essential for the clinical activity of anticancer monoclonal antibodies (mAbs), but whether PAgs affect ADCC… 

Figures from this paper

γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody

In-vitro expanded Vγ9Vδ2 T cells efficiently kill primary follicular lymphoma cells and express CD16; anti-CD20 monoclonal antibodies, in particular GA101, dramatically increase the cytotoxic activity of expanded V δ2T cells, prompting the development of clinical trials using this antibody dependent cellular cytotoxicity property.

Antibody-dependent anti-cytomegalovirus activity of human γδ T cells expressing CD16 (FcγRIIIa).

It is found that CD16 could stimulate γδ T cells independently of T-cell receptor (TCR) engagement and provide them with an intrinsic antibody-dependent cell-mediated cytotoxic (ADCC) potential.

γδ T Cells and Their Potential for Immunotherapy

Based on the results of the reported trials, γδ T cells appear to be a promising tool for novel immunotherapies against certain types of diseases.

Targeting gamma delta T cells for cancer immunotherapy: bench to bedside

Key advances in anti-tumour effector functions of γδ T cells achieved over the last few years are highlighted and the results of the clinical trials that have been done till date are summarized.

Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma

The data provide a treatment rational by PD-1 blockade aimed at boosting γδ T cell anti-tumor functions in FL and identify a PD1-regulated γ Δ T cell cytolytic immune component in FL.

γδ T Cells in the Tumor Microenvironment—Interactions With Other Immune Cells

The current understanding of these important interactions between γδ T cells and other immune cells in the context of anti-tumor immunity is reviewed and the implications of the crosstalk between T-cell receptor-dependent activation of Vγ9Vδ2+ T cells by tumors are highlighted.

Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas

Aminobisphosphonates, acting on lymph-node mesenchymal stromal cells, can push the balance towards Thelper1/effector memory and rescue the recognition and killing of lymphoma cells through NKG2D, sparing rituximab-induced antibody-dependent cell-mediated cytotoxicity.

Phosphoantigens Overcome Human TCRVγ9+ γδ Cell Immunosuppression by TGF-β: Relevance for Cancer Immunotherapy

It is reported that TGF-β does not block activation of TCRVγ9+ T cells but inhibits their PAg/IL-2–induced proliferation and maturation into effector cells and finally reduces the cytotoxic activity of these γδ T cells when exposed to lymphoma target cells.

Lymphocytes Tγδ en cancérologie - Des lymphocytes tueurs non conventionnels

Owing to their ability to directly kill tumor cells and produce inflammatory cytokines (such as IFN-gamma) boosting antitumor properties of other immune effector cells, gamma delta T cells contribute to protective immunity against cancers.

Vγ9Vδ2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies

Recent advances in the activation/expansion of γδ T cells in vitro and in vivo that may represent a promising target for the design of novel and highly innovative immunotherapy in patients with hematologic malignancies are focused on.



Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

It is demonstrated that Fc-receptor-dependent mechanisms contribute substantially to the action of cytotoxic antibodies against tumors and indicate that an optimal antibody against tumors would bind preferentially to activation Fc receptors and minimally to the inhibitory partner FcγRIIB.

Phosphostim-Activated γδ T Cells Kill Autologous Metastatic Renal Cell Carcinoma1

The results outline that Vγ9Vδ2-TCR effectors may represent a promising approach for the treatment of metastatic renal cell carcinoma.

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

In vitro studies showed the ability of C2B8 to bind human C1q, mediate complement-dependent cell lysis of human B-lymphoid cell lines, and lyse human target cells through antibody-dependent cellular cytotoxicity and the possibility of using an "immunologically active" chimeric anti-CD20 antibody as an alternative approach in the treatment of B-cell lymphoma.

Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.

The results outline that Vgamma9Vdelta2-TCR effectors may represent a promising approach for the treatment of metastatic renal cell carcinoma.

Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

This clinical trial demonstrates, for the first time, that gammadelta T-cell-mediated immunotherapy is feasible and can induce objective tumor responses.

Characterization of Tumor Reactivity of Human Vγ9Vδ2 γδ T Cells In Vitro and in SCID Mice In Vivo1

It is concluded that an effective γδ T cell-based immunotherapy might require activation of endogenous γ Δ T cells with aminobisphosphonate (or phosphoantigen) and IL-2, followed by adoptive transfer of in vitro expanded γ δ T cells.

FcγRIII discriminates between 2 subsets of Vγ9Vδ2 effector cells with different responses and activation pathways

Upon recognition of nonpeptidic phosphoantigens, human Vδ2 T lymphocytes enter a lineage differentiation pattern that determines the generation of memory cells with a range of effector functions.

In Vivo Immunomanipulation of Vγ9Vδ2 T Cells with a Synthetic Phosphoantigen in a Preclinical Nonhuman Primate Model

It is demonstrated in the cynomolgus monkey that Vγ9Vδ2 can be manipulated in vivo with bromohydrin pyrophosphate (BrHPP)/Phosphostim, a potent synthetic agonist for which the mechanism of action is similar to natural phosphoantigens.

Profiling blood lymphocyte interactions with cancer cells uncovers the innate reactivity of human gamma delta T cells to anaplastic large cell lymphoma.

In vitro trogocytosis of PKH67-stained cancer cell lines is used as a measure of their interactions with bulks of PBMC freshly isolated from healthy donors to provide interaction signatures for the immunomonitoring of cancer.

Chemical Synthesis and Biological Activity of Bromohydrin Pyrophosphate, a Potent Stimulator of Human γδ T Cells*

BrHPP is a novel molecule enabling potent immunostimulation of human γδ T lymphocytes and can be obtained in gram amounts, is easy to detect, and is of high stability in aqueous solutions.